Navigation Links
GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
Date:6/5/2008

ANN ARBOR, Mich., June 5 /PRNewswire/ -- Compendia Bioscience today announced that it has signed a two-year licensing agreement with GlaxoSmithKline (NYSE: GSK) for Oncomine(TM) Enterprise Edition, a value-added product extension Compendia's flagship product, Oncomine. Oncomine Enterprise Edition builds upon the features of Oncomine Professional and Concepts editions by integrating the ability to securely view proprietary gene expression data in comparison with existing public data already available in Oncomine.

Oncomine is a rapidly growing compendium of nearly 26,000 gene expression and DNA copy number profiles collected and curated from the literature and other public sources. These data are coupled with analysis functions and a web application for data mining and visualization. Oncomine Concepts Map, licensed to commercial users as part of the Oncomine Enterprise Edition, uses gene sets as a common language to compare and link disparate biological concepts, allowing researchers to discover and explore new biology based on signatures related to drugs and/or disease pathways.

"We are pleased to welcome GlaxoSmithKline to our growing list of major pharmaceutical and biotech customers," said John Freshley, Chief Business Officer of Compendia Bioscience. "GSK has long been a leader in the field of cancer genomics and we look forward to working closely with them to advance their oncology discovery and development efforts."

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. The Oncomine Platforms are used by thousands of cancer researchers worldwide in academic institutions as well as biotech and pharmaceutical companies to advance the molecular understanding of cancer and cancer treatment. http://www.compendiabio.com


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
9. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
10. Vaccinex Antibody Licensed to GlaxoSmithKline
11. Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... On Thursday, March 23, 2017, ... down 0.07%; the Dow Jones Industrial Average edged 0.02% ... closed at 2,345.96, marginally dropping 0.11%. US markets saw ... 4 sectors finished in red, and 1 sector ended ... reports coverage on the following Biotechnology equities: BioDelivery Sciences ...
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere ... cooking challenges for companies around the world, such as Illumina, HP and Qualcomm, and is ... for its increasing popularity is due to its new team building format, a way for ...
(Date:3/23/2017)... , March 23, 2017  GlobeImmune, Inc. today announced ... the sale of 12,835,490 shares of its common stock ... of companies. In connection with the sale of its common ... cash and issue to GlobeImmune 200,000 shares, an estimated ... "We are pleased to enter into this ...
(Date:3/23/2017)... -- NetworkNewsWire Editorial Coverage  ... Cancer remains one of the ... care systems, in terms of costs and resources. However, as ... development of innovative and efficient therapies that demonstrate higher chances ... of cancer treatments, a growing number of patients receiving immuno-oncology ...
Breaking Biology Technology:
(Date:3/6/2017)... 2017 Mintigo , the leader ... Predictive Sales Coach TM , its new artificial ... into Salesforce. This unique AI application will allow ... with deep knowledge of their customers and prospects ... Predictive Sales Coach extends Mintigo,s existing customer success ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):